tein. Then, the fusion protein was purified to near homogeneity using single-step immobilized metal affinity chromatography on a nickel-nitrilotriacetic acid affinity resin, yielding about 620 mg per liter culture. After purification, New Zealand white rabbits were immunized with purified His6-tagged VP26 in order to raise polyclonal antibody against this recombinant protein. Using the resultant sera, Western blot analysis showed that the recombinant protein was recognized by the polyclonal antibody. Conclusion: Thus, the polyclonal antibody prepared here may serve as a valuable tool to study the functional involvement of VP26 in the DPV life cycle.
DPV and have suffered considerable economic losses in the commercial duck industry due to high mortality, decreased egg production of ducks and the different lethality in wild waterfowl [1] [2] [3] [4] [5] [6] [7] [8] [9] . In China, the virulence of DPV has recently increased in geese but declined in ducks [10] . Presently, however, the molecular characteristics of DPV remain largely unknown.
DPV is composed of a linear, double-stranded DNA genome with 64.3% guanine-plus-cytosine content, which is higher than any other reported avian herpesvirus in the subfamily Alphaherpesvirinae [11] . Although DPV was previously grouped in the subfamily Alphaherpesvirinae [12, 13] , it was classified as an unassigned virus in the Herpesviridae family according to the Eighth International Committee on Taxonomy of Viruses [14] . At present, studies on the genomic organization and nucleotide sequence of DPV lag behind other members of the Herpesviridae family because most of the previous studies have focused on the epidemiology and prevention of this disease. To the best of our knowledge, neither the molecular structure of the genome nor the restriction enzyme map of DPV DNA has been published up to now [4] . To date, the majority of reported DPV sequences are limited to single open reading frames (ORFs) in the unique long (UL) region, which includes UL6 [4, 15] , UL25, UL26, UL26.5, UL27, UL28, UL29, and UL30 [16, 17] . However, no reports have been published concerning the DPV UL35 gene. Therefore, very little is known about the DPV UL35 gene or its encoding protein, VP26.
Recently, a DPV CHv-strain genomic library was constructed successfully for the first time [18] and the UL35 gene was discovered in our laboratory. In an effort to elucidate the function of VP26, we constructed a recombinant expression plasmid that drives expression of the DPV VP26 fused to His6. This plasmid was used to transform Escherichia coli BL21 (DE3) cells, which were subsequently induced to express the recombinant protein (His6-tagged VP26). His6-tagged VP26 was purified to near homogeneity using single-step immobilized metal affinity chromatography (IMAC) on a nickel-nitrilotriacetic acid (Ni 2+ -NTA) affinity resin. The purified protein was then used as an antigen for the production of polyclonal antibody specific for His6-tagged VP26.
Materials and Methods

Virus, Strains, Plasmids, Enzymes, and Other Materials
The DPV CHv strain is a high-virulence field strain of DPV that was isolated and preserved in the authors' laboratory. E. coli strain DH5 ␣ , E. coli BL21 (DE3), cloning vector pMD18-T, and expression vector pET-32a(+) were purchased from Invitrogen. Yeast extract and tryptone for bacterial medium preparation were obtained from Promega. Fetal bovine serum (FBS), antibiotics, and isopropyl-␤ -D -thiogalactopyranoside (IPTG) were bought from Novagen. Restriction enzymes, DNA ligase, Ex Taq DNA polymerase, DNA molecular weight markers, and protein molecular weight markers were obtained from TaKaRa; other reagents were offered by the Avian Diseases Research Center of the Sichuan Agricultural University. All reagents were of the highest purity that was commercially available. Purification of His-tagged protein was performed on a Ni 2+ -NTA resin (Qiagen). Here, E. coli strain DH5 ␣ was used as the cloning host for the UL35 gene encoding VP26 because of its very high transformation efficiency. For the expression of His6-tagged VP26, the E. coli strain BL21 (DE3) was used. This strain has the advantage of being deficient in both the lon and ompT proteases and harbors the T7 bacteriophage RNA polymerase gene, which permits the specific expression of heterologous genes driven by the T7 promoter [19] [20] [21] .
Preparation of DPV DNA DPV was propagated in primary duck embryo fibroblasts that were grown in Dulbecco's MEM (D-MEM; Gibco-BRL) supplemented with 10% FBS at 37 ° . For virus infection, D-MEM supplemented with 2-3% FBS was used. Viral particles were harvested when the cytopathic effect reached 75%. Cell lysates containing DPV were subjected to three freeze-thaw cycles and were then stored at -70 ° until use. The presence of DPV was confirmed by both electron microscopy and polymerase chain reaction (PCR), as described previously [15, 22] .
To isolate the nuclear DPV DNA, 5-10 ml DPV-containing cell lysate was centrifuged at 5,000 rpm for 10 min at 4 ° . The supernatant was decanted, and the cell pellet was resuspended in 2-5 ml NET (0.1 M NaCl, 1.0 m M EDTA, pH 8.0, and 10 m M Tris, pH 8.0). The cell suspension was centrifuged at 5,000 rpm for 10 min at 4 ° . Then, the supernatant was discarded and the pellet was redissolved in 750 l NET, 7.5 l proteinase K (10 mg stock), and 50 l of 15% sarcosyl. The sample was incubated at 37 ° to promote proteinase K activity. The cell lysate was then centrifuged at 12,000 rpm for 30 min at 4 ° . The nuclear DNA-containing supernatant was transferred to a fresh tube and submitted to RNase treatment at 37 ° for 1 or 2 h. DNA was extracted first with one volume of phenol (750 l), then with phenol/choloroform/isoamyl alcohol (25: 24: 1), and finally with chloroform. DNA was precipitated with two volumes of prechilled absolute ethanol and stored at -20 ° for future use.
Primer Design and PCR Amplification of the DPV UL35 Gene
The full-length DPV UL35 gene (GenBank accession No. EF643558) is composed of 354 base pairs and contains a complete theoretical ORF for a 117-residue UL35-like protein. The primers for the PCR-based amplification of this ORF were designed using the biological software Oligo6.0 and Primer5.0 and were synthesized by TaKaRa, with an expected amplified fragment of 354 bp. The upstream primer 5 GGATCC ATGTCTAATTCTGGAG-GTTCA anneals with the first 21 nucleotides of the UL35 sequence and introduces an upstream Bam HI restriction site (underlined). The downstream primer 5 AAGCTT TTATCGCT-GATCGTCTGG is complementary to the final 18 nucleotides of the UL35 sequence and introduces a Hin dIII restriction site (underlined). These restriction sites were included to facilitate the subsequent cloning procedure.
The UL35 gene was amplified by PCR from the genome of the DPV CHv strain, using DNA, which was purified as described above, as the template. PCR was performed in a 25-l reaction volume, as described previously [22] . PCR amplifications were carried out using the following reaction cycles in a commercial PCR system (2700; GeneAmp): initial denaturation at 95 ° for 5 min followed by 32 consecutive cycles of denaturation at 94 ° for 50 s, annealing for 40 s at 56 ° , and extension at 72 ° for 40 s, and then a final extension at 72 ° for 10 min, using Ex Taq DNA polymerase. The amplified product (354 bp) was analyzed by electrophoresis on a 2% (w/v) agarose gel stained with 0.5 l/ml ethidium bromide. After the PCR-amplified product had been validated as the intended product, it was purified using a PCR gel purification kit (Qiagen) according to the manufacturer's instructions. The purified PCR product was then submitted to ligation into a pMD18-T vector.
Construction of Cloning Plasmid pMD18-T/UL35
The purified PCR product was digested with Bam HI and Hin dIII restriction enzymes, purified and ligated into the correspondingly digested cloning vector pMD18-T at 16 ° overnight using T4 DNA ligase to generate a recombinant cloning plasmid named pMD18-T/UL35 ( fig. 1 ), using standard cloning methods [23] . Competent E. coli DH5 ␣ cells were transformed with the ligation mixture by the heat shock method and used for propagation of the cloning plasmid. The transformants were cultured at 37 ° on Luria-Bertani (LB) solid medium (1.0% sodium chloride, 1.0% tryptone, 0.5% yeast extract, and 1.5% agar) for 16 h and in LB liquid medium (as above but without agar) at 37 ° for 12 h, supplemented with 100 g/ml ampicillin when plasmid maintenance was required. After mini-scale isolation of plasmid DNA using the modified alkaline lysis method [24] , the presence of the appropriate insert in the obtained plasmid was verified by PCR and restriction analysis. One clone was then selected and sent to TaKaRa for sequencing.
Construction of the pET-32a(+)/UL35 Expression Plasmid
After its sequence had been confirmed, pMD18-T/UL35 was digested with Bam HI and Hin dIII restriction enzymes and submitted to electrophoresis through a 1% agarose gel, then the DNA band corresponding to the digested insert (ORF) was cut and purified from the agarose gel and directionally ligated into the previously Bam HI-/ Hin dIII-digested and dephosphorylated expression vector pET-32a(+), downstream of the T7 Lac promoter and His6 tag and upstream of the T7 terminator, to construct the recombinant prokaryotic expression vector pET-32a(+)/UL35 using T4 DNA ligase ( fig. 2 ). Cloning at the Bam HI site in pET-32a(+) results in a His6 fusion to the N-terminus of the cloned gene. This fusion tag permits purification of the produced protein by metal chelate chromatography on a nitrilotriacetic acid agarose matrix charged with nickel ions. The ligation mixture was transformed into competent E. coli DH5 ␣ cells. Positive clones with a gene insert in the plasmid were first evaluated by PCR and then reconfirmed by restriction digestion and DNA sequencing. Each identified positive colony was grown in LB medium containing ampicillin (100 g/ml). The plasmid pET-32a(+)/UL35 was isolated from the bacterial cells and used to transform the competent E. coli strain BL21 (DE3) cells for the purpose of recombinant protein expression.
Expression of the Recombinant Protein
For recombinant protein expression, E. coli strain BL21 (DE3) cells were transformed with the plasmid pET-32a(+)/UL35 and selected on LB solid medium containing ampicillin (100 g/ml). The transformants were inoculated into 5 ml of culture medium in test tubes and allowed to grow overnight at 37 ° with constant agitation (200 rpm). These cultures were used to inoculate 100 ml LB containing ampicillin (100 g/ml) and were submitted to vigorous shaking in a fermenter. When the cultures initially reached logarithmic phase (at OD 600 of 0.5-0.6), expression of the recombinant fusion protein, His6-tagged VP26, was induced by the addition of IPTG (final concentration 1.0 m M ) with further growth at 37 ° for 4 h. After induction, the cells were harvested by centrifugation at 6,000 rpm for 10 min at 4 ° and lysed in 5 ! SDS-PAGE loading buffer (0.313 M Tris-HCl, pH 6.8, 50% glycerol, 10% SDS, and 0.05% bromophenol blue, with 100 m M DTT). Then, the cell lysates were boiled for 15 min, centrifuged at 12,000 rpm for 10 min, submitted to 12% SDS-PAGE, and then analyzed by Coomassie brilliant blue R-250 staining. Briefly, the gel was stained with Coomassie brilliant blue R-250 overnight and destained in 6% acetic acid until a clear background was reached to assess the expression level of the recombinant fusion protein by densitometric scanning using Bandscan4.5 software [25] . The uninduced control culture and the vector control culture were analyzed in parallel.
To increase the production of the recombinant protein, culture conditions for expression were optimized in terms of different temperatures (30, 34, and 37 ° ), concentrations of IPTG (0, 0.2, 0.4. 0.6, 0.8, 1.0, 1.2, 1.5, and 2.0 m M ), and durations of induction (0, 1, 2, 3, 4, 5, 6, and 7 h, and overnight). Protein expression was assessed by SDS-PAGE, as described above.
For the initial experiments, which were designed to determine the solubility of the recombinant protein, log phase cultures were induced with 1 m M IPTG for 5 h at 34 ° , and approximately 4 g of wet weight cells from 1 liter of culture were harvested by centrifugation at 6,000 rpm for 10 min. The cells were left overnight at -20 ° and were then suspended in 20 ml lysis buffer of 20 m M TrisHCl buffer (pH 8.0) containing 100 m M NaCl, 1.0 m M phenylmethyl sulfonylfluoride (PMSF), and 1.0 mg/ml lysozyme. The suspension was incubated for 30 min at 4 ° with stirring and was then pulse sonicated on ice (30 s working and 30 s resting on ice, Vibrocell VCX600 sonicator, 600 W max; Sonics and Materials) until the sample was clear. Sonication was performed to release intracellular proteins. The resulting cell lysate was centrifuged at 12,000 rpm for 30 min. The clear supernatant (soluble fraction) was collected and the remaining pellets (insoluble fraction), which contained the inclusion bodies, were dissolved in deionized water and stored at -20 ° until use. Soluble and insoluble fractions were then analyzed in parallel by 12% SDS-PAGE.
Purification of the Recombinant Protein
The pellets of the insoluble fraction (crude extract) were resuspended in extraction buffer (0.5 M NaCl, 2 M urea, 1 m M DTT, 2% Triton X-100, and 20 m M Tris-HCl, pH 7.9), sonicated for 30 s at 4 ° , and centrifuged at 15,000 rpm for 30 min. The pellets were washed twice with washing buffer (0.5 M NaCl, 2 M urea, 20 m M Tris-HCl, pH 7.9), resuspended in regeneration buffer (0.5 M NaCl, 6 M urea, 20 m M Tris-HCl, pH 7.9) and incubated at room temperature (25 ° ) for 30 min. The incubated mixture was then centrifuged at 15,000 rpm for 10 min, and the resultant supernatant was submitted to further purification.
The recombinant His-tagged VP26 was purified from the supernatant obtained above by IMAC on Ni 2+ -NTA affinity resin following the manufacturer's instructions with modifications. A glass column (20 ml capacity) was packed with Ni 2+ -NTA resin matrix. The column was equilibrated with 4 bed volumes of IMAC buffer (20 m M Tris-HCl, pH 8.0, 500 m M NaCl, 0.5 m M PMSF, and 10 m M imidazole). The chromatography flow rate, which was driven by gravity, was 0.5 ml/min. The supernatant (crude extract) was loaded onto the Ni 2+ -NTA agarose resin column preequilibrated with IMAC buffer. 
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Production of Polyclonal Antibody against the Recombinant Protein
The purified recombinant protein was used for raising antibody in New Zealand white rabbits. Blood (1.5 ml) was collected prior to immunization by bleeding the rabbits from the marginal vein of the ear. This serum served as a negative control. Afterwards, the rabbits were then intradermally injected with a mixture of 500 g of purified recombinant protein mixed with an equal volume of Freund's complete adjuvant (Promega) on the back and proximal limbs (100 l/site). After 2 weeks, the rabbits were twice boosted intramuscularly with 500 g of purified recombinant protein and incomplete Freund's adjuvant at a 1-week interval. Subsequently, each rabbit was intravenously immunized with 100 g of the purified recombinant protein. Two weeks after the last injection, the rabbit with the best reactivity toward His6-tagged VP26 was sacrificed, and the antiserum was harvested from the arteriae carotis and stored at -80 ° until further use.
Purification of the Antiserum
First, the rabbit IgG fraction was precipitated from the harvested rabbit polyclonal antiserum by ammonium sulfate precipitation. Then, by using a DEAE-Sepharose column (Bio-Rad), the IgG fraction was purified by ion exchange column chromatography following the manufacturer's instructions. The purified IgG fraction was analyzed by 12% SDS-PAGE.
Western Blot Analysis
To characterize the antigenicity of the recombinant fusion protein, His6-tagged VP26, Western blot analysis was performed according to a standard procedure [27] using the purified rabbit anti-His6-tagged VP26 IgG. After the proteins had been separated by 12% SDS-PAGE, the gel was immersed in transfer buffer (0.24% Tris-HCl, 1.153% glycine, and 15% methanol, pH 8.8) and electrophoretically transferred onto nitrocellulose membrane (Bio-Rad) preequilibrated in transfer buffer using a Mini Trans Blot electrophoretic transfer cell (Bio-Rad) at 80 V for 1.5 h. The membrane was incubated in blocking buffer (5% BSA in PBS buffer) for 1 h at 37 ° or overnight at 4 ° . After three washes (10 min each) with 1 ! PBS buffer, the membrane was incubated with rabbit anti-His6-tagged VP26 IgG at a dilution of 1: 100 with 1% BSA in PBS overnight at 4 ° . The membrane was then washed three times with 1 ! PBS containing 0.1% Tween-20 (PBST), and was further incubated with horseradish peroxidase-labeled goat antirabbit IgG (Boster) at a dilution of 1: 5,000 for 1 h at 37 ° . The membrane was then washed three times with PBST and three times with PBS and developed with diaminobenzidine substrate buffer. Color development was terminated by thorough washing in distilled water.
Results and Discussion
Gene Amplification, Cloning, and Sequencing On the basis of the constructed DPV CHv-strain genomic library [18] , primers were designed to amplify the UL35 gene using DPV DNA as a template. Bam HI and Hin dIII sites were designed in the primers to facilitate subsequent cloning. The PCR product (354 bp; data not shown) was digested with Bam HI and Hin dIII restriction enzymes and the ORF was inserted into the vector pMD18-T between the Bam HI and Hin dIII sites to construct the cloning vector pMD18-T/UL35. Then, the recombinant plasmid was confirmed by DNA sequencing and restriction digestion ( fig. 3 ) . The sequencing result showed that there were no nucleotide errors in the synthetic UL35 gene fragment (data not shown). 
Construction of the Expression Plasmid
The prokaryotic expression vector pET-32a(+), which features a high stringency T7 lac promoter, His6 tag, and T7 terminator, has been recognized as one of the most powerful tools for producing recombinant proteins in E. coli [28] . The UL35 gene fragment, which was obtained by digestion of pMD18-T/UL35 with Bam HI and Hin dIII, was directionally inserted downstream of the His6-tag sequence in the pET-32a(+) plasmid to construct the expression plasmid pET-32a(+)/UL35. The initial transfor- . 4 ) . After confirmation, a positive clone was submitted to DNA sequencing and the result confirmed that the UL35 gene was in frame with the N-terminal His6 tag within the pET-32a(+) multiple cloning sites (data not shown).
Expression of the Recombinant Protein
After sequence confirmation, the recombinant plasmid pET-32a(+)/UL35 was introduced into the expression host E. coli BL21(DE3). A positive transformant was used for the subsequent induction. Initially, the induction of His6-tagged VP26 expression was carried out at 37 ° for 4 h by the addition of 1.0 m M IPTG. A distinct band of approximately 33 kDa of molecular weight, corresponding to the expected size of the His6-tagged VP26 fusion protein ( fig. 5 a, lane 9) , was observed. This result confirmed that the ORF was properly expressed in the transformed E. coli BL21 (DE3) cells. Expressed protein was not detected in the negative control E. coli BL21 (DE3) cells ( fig. 5 a, lane 3) nor was it found without induction of E. coli BL21 (DE3) cells transformed with the pET32a(+) vector ( fig. 5 a, lane 1) . Analysis of the densitometry scan of the 12% SDS-PAGE gel showed that the IPTGinduced band constituted approximately 24% of the total proteins in the induced cell extract (data not shown).
The relative distribution of the expressed recombinant protein in the soluble and insoluble fractions of the supernatant and the pellet (see Materials and Methods) of the cell lysate was examined after sonication. The recombinant protein was predominantly expressed in the insoluble fraction, in the form of inclusion bodies ( fig. 5 a,  lanes 5, 7 and 9 ), indicating that little or no soluble proteins are formed. We then tried to optimize the expression conditions as described 
Purification of the Recombinant Protein
Generally, high-level expression of recombinant proteins in E. coli often results in the formation of insoluble and inactive aggregate known as inclusion bodies [29, 30] . They develop as a result of misfolding or partial folding of polypeptides with exposed hydrophobic patches and the consequent intermolecular interactions [31] . Therefore, purified inclusion bodies must be resolubilized by strong denaturants, such as 6 M guanidine hydrochloride or 8 M urea, which promote the disruption of intermolecular interactions and complete unfolding of the protein [32, 33] . The denaturation solution is removed by dilution or a buffer exchange step [34, 35] , which permits renaturation of the proteins.
Histidine tags have become common fusion partners for recombinant proteins to facilitate purification using IMAC. For purification of the recombinant His6-tagged VP26 fusion protein from the insoluble fraction, the dissolved protein (inclusion bodies) was used as starting material and subjected to His tag purification using a single chromatographic step of IMAC on Ni 2+ -NTA agarose, as described. After elution with IMAC buffer containing 8 M urea and dialysis against PBS containing progressively lower concentrations of urea (4, 2, and 0 M ), a clear band corresponding to a molecular mass of about 33 kDa was seen on the SDS-PAGE gel following Coomassie blue staining ( fig. 6 , lane 5) . This procedure allowed to harvest ϳ 620 mg of nearly homogeneous protein (98%, accord- 
Purification of the Antiserum and Antigenicity Analysis of the Recombinant Protein
After 4 injections had been given to 6 New Zealand white rabbits, the serum containing anti-His6-tagged VP26 polyclonal antibody with the stronger specificity was collected. The rabbit anti-His6-tagged VP26 IgG, with 55 and 22 kDa of the heavy and light chains, was firstly precipitated by ammonium sulfate precipitation ( fig. 7 , lane 1) and then purified by ion exchange column chromatography ( fig. 7 , lane 2) . Western blot analysis showed that the purified His6-tagged VP26 was recognized by the rabbit anti-His6-tagged VP26 IgG and showed a specific signal at 33 kDa, which is the expected size of the fusion protein ( fig. 6 , lane 6) . Importantly, no positive signal was observed when using the negative control serum ( fig. 6 , lane 7) , indicating that the recombinant protein induced an immunological response and that the antiserum had a high level of specificity. Based upon these results, this antiserum was deemed suitable to characterize the structure, molecular mechanism, and functional involvement of the VP26 protein in the DPV life cycle.
Previous studies of the herpes simplex virus (HSV) UL35 protein of the subfamily Alphaherpesvirinae have documented that the UL35 gene acts as the real late gene ␥ 2 , which encodes a small nucleocapsid protein that is located on the hexon of the nucleocapsid. This protein interacts with the viral DNA of the nucleocapsid. It is nonessential for the formation of the viral capsid and viral propagation in cell culture, but it is essential for viral replication in the nervous system. Furthermore, the absence of this protein will result in a 100-fold reduced yield of infectious virus in the trigeminal ganglion [36] [37] [38] . This protein is located at the exterior of the icosahedral capsid, which indicates that VP26 may serve as a core that connects the capsid with the external tegument and envelope in the late stage of viral assembly [37] . The sites of this protein that are exposed on the outside of the capsid also reveal that VP26 is in a favorable position to couple the capsid and its functional ligand, such as tegument [39] . Similarly, research on the homolog of VP26 suggests that the smallest capsid protein, which is located at the most exterior region of the capsid, may play an important role in the tegumention and/or uncoating of the virion in the course of infection and in the regulation of the interaction between the capsid and tegument as well as cytoskeletal proteins [40] . Recent studies have also revealed that VP26 of HSV-1 associates with ribosomes and may regulate the host cell translation [41] . Based upon the important role played by HSV VP26 during HSV infection, we suggest that VP26 of DPV may play a similar role in the course of DPV infection. Importantly, the exact roles of DPV VP26 remain undefined.
Conclusion
In conclusion, the UL35 gene that encodes VP26 was amplified by PCR from the genome of the DPV CHv strain. It was cloned, and the recombinant protein was expressed and purified from E. coli . Western blot analyses suggest that the polyclonal antibody raised against the recombinant protein reacted with the purified recombinant protein, indicating that this specific antibody may serve as a good tool for future studies of VP26, e.g. analyses of subcellular localization, and may permit elucidation of the structure, molecular mechanism, and functional involvement of VP26 in the DPV life cycle.
